Tashko Gerti, Gabbay Robert A
Division of Endocrinology, Diabetes, and Metabolism, Penn State College of Medicine, Hershey, PA, USA;
Integr Blood Press Control. 2010;3:31-43. doi: 10.2147/ibpc.s6984. Epub 2010 May 24.
Blood pressure (BP) control is a critical part of managing patients with type 2 diabetes. Perhaps it is the single most important aspect of diabetes care, which unlike hyperglycemia and dyslipidemia can reduce both micro- and macrovascular complications. Hypertension is more prevalent in individuals with diabetes than general population, and in most cases its treatment requires two or more pharmacological agents (about 30% of individuals with diabetes need 3 or more medications to control BP). In this article we describe the key evidence that has contributed to our understanding that reduced BP translates into positive micro- and macrovascular outcomes. We review the data supporting current recommendation for BP target < 130/80 mmHg. Two studies suggest that a lower BP goal could be even more beneficial. We also present the comparative benefits of various antihypertensive drugs in reducing diabetes-related micro- and macrovascular complications. Finally we propose an evidence-based algorithm of how to initiate and titrate antihypertensive pharmacotherapy in affected individuals. Overall, achieving BP < 130/80 mmHg is more important than searching for the "best" antihypertensive agent in patients with diabetes.
血压控制是2型糖尿病患者管理的关键部分。也许它是糖尿病护理中最重要的一个方面,与高血糖和血脂异常不同,它可以减少微血管和大血管并发症。高血压在糖尿病患者中比一般人群更普遍,在大多数情况下,其治疗需要两种或更多种药物(约30%的糖尿病患者需要3种或更多药物来控制血压)。在本文中,我们描述了一些关键证据,这些证据有助于我们理解降低血压可转化为积极的微血管和大血管结局。我们回顾了支持目前血压目标<130/80 mmHg这一建议的数据。两项研究表明,更低的血压目标可能更有益。我们还介绍了各种抗高血压药物在减少糖尿病相关微血管和大血管并发症方面的比较益处。最后,我们提出了一个基于证据的算法,用于指导如何在受影响个体中启动和调整抗高血压药物治疗。总体而言,在糖尿病患者中,将血压降至<130/80 mmHg比寻找“最佳”抗高血压药物更为重要。